Last quarter (Q ), Bionoid Pharma's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q, Bionoid Pharma's net income was $-5.68M. See Bionoid Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 10	Dec 09	Dec 08	Dec 07	Dec 06
Total Revenue	-	$ 0.00	$ 0.00	$ 0.00	-	-
Cost of Revenue	$ 284.36K	$ 252.46K	$ 0.00	$ 0.00	-	-
Gross Profit	$ -284.36K	$ -252.46K	$ 0.00	$ 0.00	-	-
Operating Expense	$ 8.79M	$ 3.63M	$ 2.93M	$ 1.22M	$ 923.62K	$ 1.83M
Operating Income	$ -9.07M	$ -3.88M	$ -2.93M	$ -1.22M	$ -923.62K	$ -1.83M
Net Non Operating Interest Income Expense	$ -17.11K	$ -22.10K	$ -484.21K	$ -369.77K	-	-
Other Income Expense	-	-	-	-	-	-
Pretax Income	$ -9.09M	$ -3.91M	$ -3.41M	$ -1.59M	$ -1.26M	$ -2.08M
Tax Provision	$ 3.10K	$ 1.72K	$ 959.00	$ 863.00	$ 1.59K	$ 577.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -9.09M	$ -3.91M	$ -3.41M	$ -1.59M	$ -1.26M	$ -2.08M
Basic EPS	$ -675.00	$ -325.00	$ -0.16	$ -0.09	$ -0.08	$ -0.13
Diluted EPS	$ -675.00	$ -325.00	$ -0.16	$ -0.09	$ -0.08	$ -0.13
Basic Average Shares	$ 51.69K	$ 11.89K	$ 21.69M	$ 16.83M	$ 16.00M	$ 15.43M
Diluted Average Shares	$ 51.69K	$ 11.89K	$ 21.69M	$ 16.83M	$ 16.00M	$ 15.43M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 9.07M	$ 3.88M	$ 2.93M	$ 1.22M	$ 923.62K	$ 1.83M
Net Income From Continuing And Discontinued Operation	$ -9.09M	$ -3.91M	$ -3.41M	$ -1.59M	$ -1.26M	$ -2.08M
Normalized Income	$ -9.09M	$ -3.91M	$ -3.41M	$ -1.59M	$ -1.26M	$ -2.08M
Interest Expense	$ 17.21K	$ 22.10K	$ 484.25K	$ 369.77K	-	-
EBIT	$ -9.07M	$ -3.88M	$ -2.93M	$ -1.22M	$ -923.62K	$ -1.83M
EBITDA	$ -9.04M	$ -3.85M	$ -2.89M	$ -1.18M	$ -589.42K	$ -1.55M

Currency in USD

Bionoid Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing